PrimeraDx

PrimeraDx developed a proprietary FDA-cleared platform for quantitative multiplex molecular diagnostics with initial applications in infectious disease testing and in the development of companion diagnostics for oncology drugs. The company was acquired by Qiagen in March 2014.